Article
A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2012
Kawahara Akihiko, Taira Tomoki, Azuma Koichi, Tominaga Masaki, Hattori Satoshi, Kawahara Mayuko, Abe Hideyuki, Yamaguchi Tomohiko, Akiba Jun, Takamori Shinzo, Hayashi Akihiro, Kage Masayoshi
Abstract excerpt
BACKGROUND: We previously reported that EGFR mutation-specific antibodies performed well in immunohisto/cytochemical analysis. Assessment of EGFR mutation status for EGFR-TKIs (tyrosin kinase inhibitors) treatment of non-small cell lung cancer (NSCLC) patients can be performed by DNA-based assay. To establish a testing algorithm for EGFR mutation status in NSCLC patients, we utilized the peptide nucleic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.